Common GI Symptoms Research Articles

Prevalence of GIT Symptoms in Patients of Covid 19

Abstract Background In December 2019, a cluster of patients with pneumonia of undetermined etiology was recognized in Wuhan, Hubei, China. Subsequently, a novel coronavirus (SARS-CoV-2) was identified from lower respiratory tract samples obtained from affected patients. The clinical manifestation of COVID-19 is broad and ranges from asymptomatic and mild upper respiratory tract symptoms to severe illnesses with multiorgan failure and death. Furthermore, it is challenging to predict the clinical course or determine patients at risk of deterioration. Aim of the Work The aim of our study was to assess prevalence of GIT symptoms in patients of covid 19 infected patients Patients and Methods This study was conducted on 100 adult covid 19 patients recently diagnosed by polymerase chain reaction (PCR). All patients were submitted to clinical examination, laboratory testing for ESR, CRP, CBC, and D-dimer. Radiological investigations in the form of CT Chest were be reported by radiologist for all patients. High resolution computed tomography Parenchymal abnormalities on HRCT were assessed. Nasopharyngeal, oropharyngeal and rectal swabs were collected for COVID-19 (PCR) test. All patients received Covid-19 treatment according to protocols of WHO and ministry of health and population, Egypt. Results We found that GI symptoms are prevalent among COVID-19 Egyptian patients (64%). The most common GI symptoms were Nausea, vomiting and diarrhea. We observed that 25 patients (25%) had positive viral RNA in rectal swab. Conclusion Severe COVID-19 was more frequent in older age. Dyspnea and increased respiratory rate were associated with severity of covid 19 infection. Increased CRP and high serum levels of ferritin, d-dimer and lactate dehydrogenase were significantly associated with COVID-19 severity.

The effects of ginger supplementation on common gastrointestinal symptoms in patients with relapsing-remitting multiple sclerosis: a double-blind randomized placebo-controlled trial

BackgroundGastrointestinal (GI) symptoms affect more than 80% of individuals with relapsing-remitting multiple sclerosis (RRMS). Ginger is widely known for its GI relieving properties. Therefore, we investigated the effect of ginger supplementation on common GI symptoms in RRMS patients.MethodsThis study was a 12-week double-blind parallel randomized controlled trial with a 3-week run-in period. The intervention (n = 26) and control (n = 26) groups received 500 mg ginger and placebo (as corn) supplements 3 times a day along with main meals, respectively. At the beginning and end of the trial, the frequency and severity of constipation, dysphagia, abdominal pain, diarrhea, bloating, belching, flatulence, heartburn, anorexia, and nausea were assessed using the visual analogue scale ranging from 0 to 100 mm. Totally, 49 participants completed the study. However, data analysis was performed on all 52 participants based on the intention-to-treat principle.ResultsIn comparison with placebo, ginger supplementation resulted in significant or near-significant reductions in the frequency (-23.63 ± 5.36 vs. 14.81 ± 2.78, P < 0.001) and severity (-24.15 ± 5.10 vs. 11.39 ± 3.23, P < 0.001) of constipation, the frequency (-12.41 ± 3.75 vs. 3.75 ± 1.82, P < 0.001) and severity (-13.43 ± 4.91 vs. 6.88 ± 2.69, P = 0.001) of nausea, the frequency (-9.31 ± 4.44 vs. 1.56 ± 4.05, P = 0.098) and severity (-11.57 ± 5.09 vs. 3.97 ± 3.99, P = 0.047) of bloating, and the severity of abdominal pain (-5.69 ± 3.66 vs. 3.43 ± 3.26, P = 0.069).ConclusionGinger consumption can improve constipation, nausea, bloating, and abdominal pain in patients with RRMS.Trial RegistrationThis trial was prospectively registered at the Iranian Registry of Clinical Trials (www.irct.ir) under the registration number IRCT20180818040827N3 on 06/10/2021.

S3910 Case Report of Paroxysmal Nocturnal Hemoglobinuria and Small Intestinal Ulcers: A Rare Finding With Common GI Symptoms

S3910 Case Report of Paroxysmal Nocturnal Hemoglobinuria and Small Intestinal Ulcers: A Rare Finding With Common GI Symptoms

Prevalence of Different Gastrointestinal Manifestations in Patients with Covid 19 Presenting to Gastroenterology OPD at Rawal Institute of Health Sciences, Islamabad

Objective: The objective behind this study was to determine the prevalence of different gastrointestinal manifestations in patients with COVID-19 presenting to gastroenterology OPD at Rawal Institute of health sciences, Islamabad Methods: this was a descriptive observational hospital-based study conducted through a convenient sampling technique. All the adult males and females diagnosed as COVID-19 for the first time were included in this study. Pregnant females, concomitant viral hepatitis, typhoid fever, known gastrointestinal disease, and those who did not consent to participate were excluded from this study. Proforma was used to collect the relevant data. Data regarding GI symptoms were collected and presented in the form of frequency and percentages. Results: Final analysis was performed on 193 COVID-19 positive patients. Diagnosed patients were mostly young with mean age was 39.42±18.29 years. More than 68% of the patients were males. Sixty-eight (35.23%) of the COVID-19 PCR positive patients presented with symptoms of gastrointestinal manifestations and the most common GI symptom was presence of Dysgeusia (52.94%, n = 36). Conclusions: Most of our study subjects belongs to young age group. The prevalence of GI manifestations are quite high as observed in our study and the most common GI symptoms was dysgeusia. Keywords: COVID-19 infection, gastrointestinal symptoms, clinical manifestation, Pakistan

A study of socio clinical, biochemical and electrocardiographic changes of yellow oleander seed poisoning in India

Yellow oleander (Thevetia peruviana), which belongs to the Apocyanaceae family, is a common shrub seen throughout the tropics. All parts of the plant contain high concentrations of cardiac glycosides, which are toxic to cardiac muscle and the autonomic nervous system. The main objective of this study was to socio-clinical, biochemical and electrocardiographic changes of yellow oleander seed poisoning. This prospective observational study was conducted over a period of 6 months (March 2022 to September 2022). Oleander seed poison in most prevalent in the 21–40 years age. More the crushed seeds consumed and the delay to admission to the hospital for treatment poorer was the outcome. The most common GI symptoms of yellow oleander poisoning were vomiting (58 %), abdominal pain (28%), diarrhoea (9%), and palpitations (20%), dizziness (18%).Serum potassium levels that were measured during the admission were directly related to the ECG changes. ECG changes were more observed with patients those who consumed seeds in crushed form and this difference is statistically significant (P = 0.0001). Higher incidence of cardiotoxicity was noted with patients those who consumed poison on empty stomach compare to who consumed after food. The Electrocardiographic manifestations was found even with consumption of one seed, number of seeds consumptions independent of cardiotoxicity.Additonally higher mean Potassium value observed in patients who had cardiotoxicity when compared to patient who had no cardiotoxicity. Death of the patients in yellow oleander seed poisoning was independent of quantity of the seeds they have ingested.

A study of socio clinical, biochemical and electrocardiographic changes of yellow oleander seed poisoning in India.

Yellow oleander (Thevetia peruviana), which belongs to the Apocyanaceae family, is a common shrub seen throughout the tropics. All parts of the plant contain high concentrations of cardiac glycosides, which are toxic to cardiac muscle and the autonomic nervous system. The main objective of this study was to socio-clinical, biochemical and electrocardiographic changes of yellow oleander seed poisoning. This prospective observational study was conducted over a period of 6 months (March 2022 to September 2022). Oleander seed poison in most prevalent in the 21-40 years age. More the crushed seeds consumed and the delay to admission to the hospital for treatment poorer was the outcome. The most common GI symptoms of yellow oleander poisoning were vomiting (58 %), abdominal pain (28%), diarrhoea (9%), and palpitations (20%), dizziness (18%).Serum potassium levels that were measured during the admission were directly related to the ECG changes. ECG changes were more observed with patients those who consumed seeds in crushed form and this difference is statistically significant (P = 0.0001). Higher incidence of cardiotoxicity was noted with patients those who consumed poison on empty stomach compare to who consumed after food. The Electrocardiographic manifestations was found even with consumption of one seed, number of seeds consumptions independent of cardiotoxicity.Additonally higher mean Potassium value observed in patients who had cardiotoxicity when compared to patient who had no cardiotoxicity. Death of the patients in yellow oleander seed poisoning was independent of quantity of the seeds they have ingested.

Distinct diarrhea profiles during outpatient chemotherapy.

Chemotherapy-induced diarrhea (CID) is a common symptom that occurs in 50 to 80% of patients. Given that the majority of the data on the occurrence and severity of CID is based on physician-rated toxicity criteria, this study's purposes were to identify subgroups of patients with distinct CID profiles and determine how these subgroups differ in terms of demographic and clinical characteristics; severity, frequency, and distress of CID; the co-occurrence of common GI symptoms; and QOL. Patients (n= 1133) completed the Memorial Symptom Assessment Scale six times over two cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct diarrhea profiles. Differences among these subgroups were evaluated using parametric and nonparametric statistics. Four distinct diarrhea profiles were identified: none (58.3%), decreasing (22.0%), increasing (5.2%), and high (14.5%). Compared with the none class, patients in the high class had a lower functional status, a worse comorbidity profile, were more likely to have gastrointestinal cancer, and were more likely to receive chemotherapy on a 14-day cycle. No differences were found among the classes in the percentages of patients who received chemotherapy with a targeted therapy. Given that CID occurred in over 40% of the patients, clinicians should assess for this symptom and other common GI symptoms and initiate appropriate pharmacologic and dietary interventions.

Clinical manifestations and associated disorders in children with celiac disease in southern Iran

BackgroundCeliac disease (CD) is an immune mediated inflammatory enteropathy, triggered by gluten exposure in HLA-DQ2 and/or –DQ8 genetics. The presentation of celiac disease in children is changing, with increase in non-classical symptoms. We aim to evaluate the clinical presentations of celiac disease amongst children, diagnosed with CD.MethodsIn this cross sectional study, we investigated the clinical features of 130 celiac patients at hospitals affiliated with Shiraz University of Medical Sciences. We used their hospital charts and conducted an interview with patients and their parents to find out demographic data, symptoms, laboratory, and histopathology findings for Marsh grading.ResultsCeliac disease was detected more amongst females (63.8%). We found that 5.4% of the patients had BMI more than 95th percentile. The most common GI symptoms were abdominal pain, flatulence and constipation. Also, the most common extra intestinal manifestation included bone pain, long term fatigue and anemia. Flatulence, chronic diarrhea, and paresthesia were observed more amongst male participants. The most common comorbidities were type 1 diabetes mellitus and hypothyroidism.ConclusionThe most common gastrointestinal symptoms amongst our patients were abdominal pain, flatulence and constipation. Furthermore, the most common extra intestinal manifestations included bone pain, long term fatigue and anemia. The most associated comorbidities with CD in our children were type 1 diabetes mellitus and hypothyroidism.

Population-based assessment of gastrointestinal symptoms and diseases: Cappadocia Cohort, Turkey.

The aim of this study was to determine the prevalence of symptoms and diseases of the lower and upper gastrointestinal system (GIS) in a population-based sample. The cross-sectional cohort study was conducted in Cappadocia cohort comprising the Gülşehir and Avanos districts. The "Gastrointestinal Symptom Questionnaire" was applied to persons over the age of 18 years. The GI Symptom Questionnaire was applied to 3369 subjects, and height and body weight were measured in 2797 consenting subjects. Of the participants, 61% were female and the mean patient age was 50±15 years. At least one GI symptom was present in 70.6% of the cohort. The most common upper GI symptoms were gastric bloating (31.0%) and heartburn (29.1%). The most common lower GI symptom was abnormal defecation (33.5). The prevalence of upper GIS and lower GIS diseases was 32.7% and 12.9%, respectively, and the prevalence of togetherness of upper and lower GIS diseases was 9.9%. Prevalence of GIS disease was approximately 3 times higher in females (p<0.001). All of the upper and lower GI symptoms and the prevalence of upper GIS disease increased in line with Body mass index (BMI). This first population-based, cross-sectional cohort study revealed that the prevalence of GIS diseases is critically high for optimal public health. Special attention must be paid to these diseases while planning health policies and reimbursements.

Gastrointestinal symptoms in patients with diabetes mellitus and non-diabetic: A cross-sectional study in north of Iran

Background and aimGastrointestinal (GI) symptoms are common in patients with diabetes mellitus (DM), which involved in high cost of health care and low quality of life. The aim of this study to investigate the prevalence of GI symptoms in diabetic patients referred to the Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences (Rasht, Iran) using a validated questionnaire. MethodsIn this descriptive, cross-sectional study, 255 diabetic patients and 255 non-diabetic subjects were recruited. Participants were randomly selected. The questionnaire recorded GI symptoms among the study population. ResultsGI symptoms were reported in 91.4% of diabetic patients, and 42.1% of them were male. The common GI symptoms in diabetic patients were flatulence (33.0%), followed by retrosternal pain (14.9%), belching (13.7%), postprandial fullness (12.5%), and constipation (11.4%). Retrosternal pain, constipation, flatulence, loss of appetite, and abdominal distention were more prevalent in diabetic women than men. ConclusionsDM is associated with high prevalence rate of upper and lower GI symptoms. This effect may be linked to gender and poor glycemic control in diabetic patients, but not to type and duration of diabetes.

Using Search Engine Query Data to Explore the Epidemiology of Common Gastrointestinal Symptoms.

Internet searches are an increasingly used tool in medical research. To date, no studies have examined Google search data in relation to common gastrointestinal symptoms. The aim of this study was to compare trends in Internet search volume with clinical datasets for common gastrointestinal symptoms. Using Google Trends, we recorded relative changes in volume of searches related to dysphagia, vomiting, and diarrhea in the USA between January 2008 and January 2011. We queried the National Inpatient Sample (NIS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) during this time period and identified cases related to these symptoms. We assessed the correlation between Google Trends and these two clinical datasets, as well as examined seasonal variation trends. Changes to Google search volume for all three symptoms correlated significantly with changes to NIS output (dysphagia: r=0.5, P=0.002; diarrhea: r=0.79, P<0.001; vomiting: r=0.76, P<0.001). Both Google and NIS data showed that the prevalence of all three symptoms rose during the time period studied. On the other hand, the NHAMCS data trends during this time period did not correlate well with either the NIS or the Google data for any of the three symptoms studied. Both the NIS and Google data showed modest seasonal variation. Changes to the population burden of chronic GI symptoms may be tracked by monitoring changes to Google search engine query volume over time. These data demonstrate that the prevalence of common GI symptoms is rising over time.

The effect of subthalamic deep brain stimulation on gastric motility in Parkinson's disease

ObjectiveDeep brain stimulation of the subthalamic nucleus (STN-DBS) is well established for treating the motor symptoms for advanced Parkinson's disease (PD) but its effects on gastric myoelectrical activity and gastrointestinal symptoms have not been well studied. The aim of this study was to evaluate the effect of STN-DBS on gastric motility using electrogastrography (EGG). MethodsTwenty patients with PD (5 females, 15 males; mean aged 58.0 ± 9.0 years) who underwent STN-DBS were studied. EGG was performed in fasting and postprandial conditions before STN-DBS and 3 months after the surgery. We also evaluated the frequency and severity of gastrointestinal symptoms based on a structured gastrointestinal dysfunction questionnaire. ResultsAfter STN-DBS the percentage of normogastria (47.8 ± 20.7 vs 51.3 ± 15.1) and period dominant power (PDP) (11.8 ± 1.2 vs 12.3 ± 0.9) significantly increased, the percentage of arrhythmia decreased compared to the baseline during fasting and postprandial state. Abnormal response to a meal (power ratio of PDP <1 after meal) decreased from 70% to 55% after 3 months follow-up. The abnormal EGG (the percentage of normogastria <70%) decreased in both fasting (from 80% to 65% patients) and postprandial state (from 80% to 60% patients), respectively after the surgery. The most common GI symptoms reported prior to the surgery were constipation 95%, difficulty with defecation 85% and dysphagia 50%. After STN-DBS all gastrointestinal symptoms improved, the greatest improvement was observed in difficulty with defecation. ConclusionOur results suggest that STN-DBS improves gastric motility as well as gastrointestinal symptoms in PD. Further studies of gastrointestinal motility in PD are warranted.

Gastrointestinal signs and symptoms among persons with diabetes mellitus.

To determine the prevalence of gastrointestinal symptoms and signs among persons with diabetes mellitus in a specialist hospital. Gastrointestinal symptoms and signs are common among patients with diabetes mellitus. Morbidity from. In this descriptive, cross-sectional study, subjects from the general population with diabetes (n=200) were recruited for this study. Subjects were randomly chosen from patients known to have diabetes, (type I&II), attending the diabetes clinic at Sina University Hospital, in Tabriz during 2003. The questionnaire recorded gastrointestinal symptoms among the subject population. 91% and 9% of patients had Type II and I diabetes, respectively. Sixty seven percent of them had poor controlled diabetes and only 3% had well controlled diabetes. Gastrointestinal symptoms and signs were reported in 92% of patients. The common GI symptoms were constipation (59.5%), followed by bloating (44%), abdominal pain (31%), dyspepsia (30%), and mass protruding through anus (22.5%). Abdominal tenderness on deep palpation was the commonest clinical sign (54%). GI symptoms were more prevalent in subjects aged 60-69 years (97.2%). Seventy four percent of patients with GI signs and symptoms had complications such as neuropathy 61.5% and retinopathy associated with neuropathy 38.5%. The prevalence of GI symptoms and signs in the population studies was higher than that reported from other populations, and there is a relationship between glycaemic control and complications of diabetes in diabetic subjects.

First year of fellowship: lessons learned

First year of fellowship: lessons learned

The Burden of Gastrointestinal and Liver Diseases, 2006

Digestive and liver diseases are a source of significant morbidity, mortality, and health-care costs for the U.S. population. An annual report of the toll of these diseases could be helpful to clinicians, policymakers, and researchers. To describe the epidemiology of gastrointestinal and liver diseases in the United States using data from privately and publicly held databases. We collected data from the National Center for Health Statistics, the National Ambulatory Medical Care Survey, the National Inpatient Sample, the Centers for Disease Control and Prevention, and the National Cancer Institute, as well as proprietary pharmaceutical databases to construct a report on the impact of gastrointestinal and liver diseases on the U.S. population. We compiled information on causes of death, hospitalization, clinic visits, cancer incidence, and mortality and infectious disease incidence from these databases, and extracted data specific to gastrointestinal diseases. Because of the high costs associated with medications used to treat gastrointestinal diseases, we also include in this year's report a special section on pharmacoepidemiology and pharmacoeconomics. Colorectal cancer continues to be the leading cause of GI-related death, although the data indicate a downward trend in deaths. Abdominal pain, diarrhea, vomiting, and nausea are the most common GI symptoms precipitating a visit to the physician, and GERD is the most common GI-related diagnosis given in office visits. Chest pain not specified to be cardiac in origin is the most common cause of inpatient admission possibly related to GI disease, with cholelithiasis and pancreatitis following. Americans spend in excess of US dollars 10 billion/yr on proton pump inhibitors (PPIs), and two of the top five selling drugs in the United States are PPIs. Trends in PPI use demonstrate turbulent changes, likely reflecting both new drug entries into the field, as well as drug marketing. The number of PPI prescriptions/yr in the United States has doubled since 1999. Twenty-three drugs used for gastrointestinal diseases are among the top 200 generic drugs used in the United States. Gastrointestinal and liver diseases are significant contributors to the morbidity, mortality, and health-care expenditures of the U.S. population.

Symptom clustering in subjects with and without diabetes mellitus: a population-based study of 15,000 Australian adults

Objectives GI symptoms form distinct symptom clusters in community samples when factor and cluster analysis is applied. However, this has not been studied in diabetic populations, despite clear evidence that GI complaints are common in patients with diabetes mellitus (DM). This study aimed to describe clustering of GI symptoms among individuals with and without diabetes mellitus, and to describe associations of symptom clustering in diabetes mellitus, with self-reported glucose control and treatment. Methods A large population survey (n = 15,000) was used to identify a cohort with diabetes mellitus. Items assessing therapy and quality of glycemic control were included, as were those assessing 16 common GI symptoms. Latent GI symptom factors were extracted by factor analysis and used in a k-means cluster analysis. The latter serves to group individuals according to commonalities in symptom profiles. The association of cluster group membership to glycemic control and diabetic treatment was described by logistic regression. Results Factor analysis identified four latent symptom factors, which accounted for 69.3% of the total variance. These were labeled Upper GI/Dysmotility, Diarrhea, Constipation, and Vomiting/Nausea. The k-means analysis produced a five-cluster solution, which included a “health” group and four “diseased” groups, each identified by a predominant symptom: Upper GI/Dysmotility symptoms, Nausea/Vomiting, Diarrhea, and Constipation. After adjustment for age and gender, poor glycemic control predicted membership in all disease clusters, when compared separately with the health group. Oral hypoglycemic drugs predicted membership in the Nausea/Vomiting cluster (OR = 5.13) when used alone, and membership in the Nausea/Vomiting (OR = 10.12) and Upper GI/Dysmotility cluster (OR = 10.12) when used in combination with insulin. Conclusion Diabetes can be grouped according to common GI symptoms. Glycemic control and treatment for DM predict membership of symptom clusters.

Symptom clustering in subjects with and without diabetes mellitus: a population-based study of 15,000 Australian adults.

GI symptoms form distinct symptom clusters in community samples when factor and cluster analysis is applied. However, this has not been studied in diabetic populations, despite clear evidence that GI complaints are common in patients with diabetes mellitus (DM). This study aimed to describe clustering of GI symptoms among individuals with and without diabetes mellitus, and to describe associations of symptom clustering in diabetes mellitus, with self-reported glucose control and treatment. A large population survey (n = 15,000) was used to identify a cohort with diabetes mellitus. Items assessing therapy and quality of glycemic control were included, as were those assessing 16 common GI symptoms. Latent GI symptom factors were extracted by factor analysis and used in a k-means cluster analysis. The latter serves to group individuals according to commonalities in symptom profiles. The association of cluster group membership to glycemic control and diabetic treatment was described by logistic regression. Factor analysis identified four latent symptom factors, which accounted for 69.3% of the total variance. These were labeled Upper GI/Dysmotility, Diarrhea, Constipation, and Vomiting/Nausea. The k-means analysis produced a five-cluster solution, which included a "health" group and four "diseased" groups, each identified by a predominant symptom: Upper GI/Dysmotility symptoms, Nausea/Vomiting, Diarrhea, and Constipation. After adjustment for age and gender, poor glycemic control predicted membership in all disease clusters, when compared separately with the health group. Oral hypoglycemic drugs predicted membership in the Nausea/Vomiting cluster (OR = 5.13) when used alone, and membership in the Nausea/Vomiting (OR = 10.12) and Upper GI/Dysmotility cluster (OR = 10.12) when used in combination with insulin. Diabetes can be grouped according to common GI symptoms. Glycemic control and treatment for DM predict membership of symptom clusters.

Assessment of the Nutritional Effects of Olestra, a Nonabsorbed Fat Replacement: Summary ,

Olestra is a zero-calorie fat replacement intended to replace 100% of the fat used in the preparation of savory snacks. Olestra can affect the absorption of other dietary components, especially highly lipophilic ones, when ingested at the same time. The potential effects of olestra on the absorption of essential fat-soluble and water-soluble dietary components have been investigated in pigs and in humans. In these studies, subjects were fed daily amounts of olestra up to 10 times the estimated mean intake from savory snacks and the olestra was eaten each day of the studies. In real life, snacks are eaten on average five times in a 14-d period. Olestra did not affect the availability of water-soluble micronutrients or the absorption and utilization of macronutrients. Olestra reduced the absorption of fat-soluble vitamins A, D, E and K; however, the effects can be offset by adding specified amounts of the vitamins to olestra foods. Olestra also reduced the absorption of carotenoids; analysis of dietary patterns showed that in real life the reduction will likely be <10%. Any effect on vitamin A stores caused by a reduction in carotenoid uptake is offset by the addition of vitamin A to olestra foods. Because of the olestra-to-nutrient ratios fed and the nutritional requirements of the test subjects, the effects of olestra on nutritional status of subgroups of the population are unlikely to be different than those measured in the studies. An analysis of lipophilicity showed that olestra is unlikely to significantly affect the uptake of potentially beneficial phytochemicals from fruits and vegetables. Some people eating large amounts of olestra snacks may experience common GI symptoms such as stomach discomfort or changes in stool consistency, similar to symptoms accompanying other dietary changes. These symptoms present no health risks.